Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

 Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

Roche Reports Kadcyla (trastuzumab emtansine) vs Herceptin (trastuzumab) Achieve 1EP in P-III KATHERINE study

Shots:

  • The P-III KATHERINE study involves assessing of Kadcyla vs Herceptin + taxane-based CT as an adjuvant treatment in people with HER2-positive early breast cancer (eBC) who didn’t achieve pathological complete response to neoadjuvant treatment
  • The P-III KATHERINE study met 1EP endpoints i.e. iDFS the time period to invasive breast cancer recurrence or death. No new safety signals were observed & included DFS & OS as 2EP
  • Kadcyla is an Ab-drug conjugate (ADC) for inducing CT into HER2-positive cancer cells, approved drug in 104 countries including the US and EU. Roche is licensing a technology for Kadcyla from ImmunoGen

Click here to read full press release/ article | Ref: Roche | Image: Fierce Biotech

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post